Summary
Elevance Health, Inc. (ELV) has filed an 8-K report on November 10, 2025, primarily to reaffirm its financial guidance for the full year 2025 during upcoming investor meetings. The company expects to maintain its previously issued earnings per diluted share guidance of approximately $24.70. This figure notably includes approximately $5.30 per diluted share attributable to net unfavorable items. Excluding these specific items, Elevance Health anticipates adjusted earnings per diluted share to remain at approximately $30.00, consistent with prior expectations and not incorporating any additional adjustments beyond those already reported in the third quarter of 2025. In addition to earnings guidance, the company also reaffirmed its full-year 2025 benefit expense ratio guidance, projecting it to be around 90.0%. Management attributes these expectations to their current assessment of market conditions, operational performance, the prevailing regulatory and policy environment, and refined business assumptions, including cost trends and medical claims payable estimates. Investors are reminded that actual results could materially differ from these projections due to potential changes in business factors or underlying assumptions.
Key Highlights
- 1Elevance Health reaffirms full-year 2025 earnings per diluted share guidance of approximately $24.70.
- 2Net unfavorable items are estimated to impact EPS by approximately $5.30 per diluted share for FY2025.
- 3Adjusted earnings per diluted share guidance for FY2025 remains at approximately $30.00.
- 4The company expects the benefit expense ratio for full-year 2025 to be approximately 90.0%.
- 5Guidance reaffirmation is based on current market conditions, operational performance, regulatory landscape, and refined business assumptions.
- 6The report includes forward-looking statements and a cautionary note about potential material differences in actual results.